High dose intravenous oestrogen (Fosfestrol) in the treatment of symptomatic, metastatic, hormone-refractory carcinoma of the prostate

International Urology and Nephrology

Volumn 30, Issue 2, 1998, Pages 159-164

  Ahmed, M ^a   Choksy, S ^a   Chilton, C P ^a   Munson, K W ^a   Williams, J H ^a  

^a DERBY CITY GENERAL HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DIETHYLSTILBESTROL; FOSFESTROL; PROSTATE SPECIFIC ANTIGEN;

ADULT; ARTICLE; BONE PAIN; CLINICAL ARTICLE; CLINICAL TRIAL; CYTOTOXICITY; ESTROGEN THERAPY; HORMONAL REGULATION; HORMONAL THERAPY; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; NEGATIVE FEEDBACK; PATIENT SELECTION; PROSTATE CARCINOMA; RELAPSE; SCORING SYSTEM; TREATMENT INDICATION; TREATMENT OUTCOME;

EID: 0031783561     PISSN: 03011623     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02550571     Document Type: Article

References (13)

1. Isaac, J. T., Schulz, I. I., Coffey, D. S.: Development of androgen resistance in prostatic cancer. In: Murphy, G., Khoury, S., Kuss, R., Chatelain, C., Denis, L. (eds): Prostate Cancer, Part A. Research: Endocrine Treatment and Histopathology. Alan R. Liss, New York 1987, pp. 21-31.
2. Fossa, S. D., Aaronson, N. K., Newling, D.: Quality of life in and treatment of hormone resistant metastatic prostatic cancer. Eur. J. Cancer, 26. 1133 (1990).
3. George, N. J. R.: Natural history of localized prostatic carcinoma managed by conservative therapy alone. Lancet, 1, 494 (1988).
4. Dearnaley, D. P., Bayly, R. J., A'Hern, R. P., Gadd, J., Zivanovic, M. M., Lewington, V. J.: Palliation of bone metastasis in prostate cancer, hemibody irradiation or strontium-89. Clin. Oncol., 4, 101 (1992).
5. Klijn, J. G. M.: Scientific background of hormonal treatment of prostatic cancer. In: EORTC Genitourinary Group Monograph 7. Prostate Cancer and Testicular Cancer. Wiley-Liss, New York 1990, pp. 7-22.
6. Thompson, T. C.: Growth factors and oncogenes in prostate cancer. Cancer Cells, 2, 345 (1990).
7. Ferro, M. A., Heinemann, D., Smith, P. J. B., Symes, M. O.: The effect of stilboestrol and testosterone on the incorporation of 75-selenomethionine by prostatic carcinoma cells. Br. J. Urol., 62 (2), 166 (1988).
8. Schulz, P., Vetter, I., Fittler, F.: Evaluation of cytotoxic activity of stilboestrol and its phosphorylated derivative towards prostatic carcinoma, non-prostatic neoplastic and non-transformed cells. Urol. Int., 43 (Suppl. 1), 5 (1988).
9. Schneider, M. R., Schonenberger, H.: Effects of diethylstilboestrol and its mono- and diphosphate on experimental mammary and prostatic tumors. Urol. Int., 43 (Suppl. 1), 5 (1988).
10. Ferro, M. A., Gillatt, D., Symes, M. D., Smith, P. J. B.: High-dose intravenous estrogen therapy in advanced prostatic carcinoma: Use of serum prostate-specific antigen to monitor response. Urology, 34 (3), 134 (1989).
11. Mahler, C., Keuppens, F., Nowe, P., Van Erps, P., Denis, L.: Prospective study of diethylstilboestrol-diphosphate in the treatment of prostate cancer in relapse. Urol. Int., 43 (Suppl. 1)., 47 (1988).
12. Brandes, D., Bourne, G. H.: Stilboestrol phosphate and prostatic carcinoma. Lancet, 1, 481 (1955).
13. Droz, J P., Kattan, J., Bannau, M., Chraibu, Y., Bekradda, M.: High-dose continuous-infusion Fosfestrol in hormone-resistant prostate cancer. Cancer, 71 (Suppl. 3), 1123 (1993).